GILEAD SCIENCES SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 155
- Registration Number
- NCT02836236
- Locations
- 🇨🇳
Beijing Ditan Hospital, Beijing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Youan Hospital, Capital Medical University, Beijing, China
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
- First Posted Date
- 2016-07-04
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 117
- Registration Number
- NCT02822794
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 57
- Registration Number
- NCT02808312
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT02783976
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 220
- Registration Number
- NCT02781584
- Locations
- 🇺🇸
Pinnacle Clinical Research, PLLC, San Antonio, Texas, United States
🇺🇸American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
🇺🇸Gastro One, Germantown, Tennessee, United States
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 79
- Registration Number
- NCT02781571
- Locations
- 🇪🇸
Hospital Ramón Y Cajal, Madrid, Spain
🇪🇸La Fe Hospital, Valencia, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 204
- Registration Number
- NCT02781558
- Locations
- 🇪🇸
Hospital Universitario Donostia, San Sebastian, Spain
🇪🇸Hospital Universitario Virgen De La Arrixaca, Murcia, Spain
🇪🇸Complexo Hospitalario Universitario de Montecelo, Pontevedra, Spain
Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 6
- Registration Number
- NCT02759562
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3
- Registration Number
- NCT02739360
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 239
- Registration Number
- NCT02738333
© Copyright 2024. All Rights Reserved by MedPath